Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan Eisai Apr 23, 2021 13:55 HKT/SGT Read More
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies Eisai Apr 23, 2021 12:02 HKT/SGT Read More
Avance Clinical社がOracle Health Sciences Connectで「Decentralized Trials - No Going Back」と題した講演に招待されました Avance Clinical Apr 23, 2021 12:00 JST Read More
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease Eisai Apr 23, 2021 08:07 HKT/SGT Read More
Avance Clinical Invited to Present "Decentralized Trials - No Going Back" for Oracle Health Sciences Connect Avance Clinical Apr 22, 2021 13:00 JST Read More
エーザイ、Lecanemab（BAN2401）の早期アルツハイマー病に対する18カ月の臨床第IIb相試験の結果が査読学術専門誌Alzheimer's Research and Therapy誌に掲載 Eisai Apr 20, 2021 11:00 JST Read More
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Eisai Apr 20, 2021 08:23 HKT/SGT Read More
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting Eisai Apr 14, 2021 12:49 HKT/SGT Read More
エーザイ、リンパ系フィラリア症の制圧活動に関するアニメーション動画がInternational Society for Neglected Tropical Diseasesフェスティバルアワード2021で「アニメーション賞」を受賞 Eisai Apr 12, 2021 14:00 JST Read More
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 Eisai Apr 12, 2021 12:16 HKT/SGT Read More
Hitachi and Axcelead to start joint development of solutions for the efficient creation of next-generation biopharmaceuticals Hitachi, Ltd. Apr 07, 2021 14:32 HKT/SGT Read More
Chubu Miraiz and MC Launch New Assisted-Living JV Mitsubishi Corporation Apr 01, 2021 17:55 HKT/SGT Read More
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries Eisai Mar 31, 2021 20:22 HKT/SGT Read More
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan Eisai Mar 31, 2021 20:18 HKT/SGT Read More
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab Eisai Mar 30, 2021 11:42 HKT/SGT Read More
